FDA Approves New Drug to Prevent RSV in Babies and Toddlers

The Asthma and Allergy Foundation of America (AAFA) is sharing this press release from the Food and Drug Administration (FDA) to bring you the latest research news. [PRESS RELEASE] FDA Approves New Drug to Prevent RSV in Babies and Toddlers Today, the U.S. Food and Drug Administration approved Beyfortus (nirsevimab-alip) for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants born during or entering their first RSV season, and in…

Lesen Sie weiter auf: FDA Approves New Drug to Prevent RSV in Babies and Toddlers
Quelle: Asthma and Allergy Foundation of America
Titelbild/Grafik by Asthma and Allergy Foundation of America (AAFA)

Kommentare und Fragen

Möchten Sie zu diesem Artikel ein Kommentar abgeben oder haben Sie dazu eine Frage, dann machen Sie dies bitte immer auf der Herausgeberseite!

Weiteres von Asthma and Allergy Foundation of America

• Uncontrolled Asthma? A Biologic May Be an Option for You
• Change-Makers for Asthma and Allergies
• Can a Simple Invitation Change Your Life?
• November Research Update: Asthma, HES, Sesame Labeling, and CSU
• Impact And Inspiration: 2023 AAFA Accomplishments
• RSV, Asthma, and You – What You Need to Know This RSV Season (Video)
• The Power of the Patient Voice in Asthma and Allergy Research
• Managing Your Asthma to Reduce Symptoms and Preserve Lung Function – Video
• Health Insurance Marketplace Guide for Asthma and Allergies for 2024
• Health Insurance 101: Open Enrollment